<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03401112</url>
  </required_header>
  <id_info>
    <org_study_id>IMR-SCD-102</org_study_id>
    <nct_id>NCT03401112</nct_id>
  </id_info>
  <brief_title>A Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)</brief_title>
  <official_title>A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imara, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imara, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2a randomized, placebo-controlled, multicenter study of orally administered IMR-687
      in adults with Sickle Cell Anaemia (SCA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a proof of concept study in adult SCA patients, age 18-50 years old. The primary goal
      is to examine the safety, pharmacokinetics and preliminary pharmacodynamics of escalating
      doses of IMR-687 as compared to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (safety and tolerability).</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Proportion of patients with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of IMR-687 (Cmax)</measure>
    <time_frame>1, 4 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Curve (AUC) of IMR-687</measure>
    <time_frame>1, 4 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of hydroxyurea</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of hydroxyurea</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>PBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMR-687</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMR-687</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMR-687</intervention_name>
    <description>Oral administration of once daily IMR-687</description>
    <arm_group_label>PBO</arm_group_label>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with confirmed SCD

          -  Age 18-50 years, inclusive

          -  For patients on hydroxyurea, must have been on a stable dose for at least 60 days
             prior to screening

        Exclusion Criteria:

          -  Total hemoglobin &gt;11 or less than 6 g/dL

          -  RBC transfusion within 60 days of baseline

          -  &gt;3 hospitalizations for vasoocclusive crises within the last year

          -  eGFR &lt; 50 ml/min

          -  AST/ALT &gt; 3x the upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Mant, MB, FFPM,FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas Hospital CRF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ShiYin Foo, MD PhD</last_name>
    <phone>617-231-6020</phone>
    <email>syfoo@imaratx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Warner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham and Sandwell</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Green</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Croydon Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Sawyerr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jitka Fucikova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Homerton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Price</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

